Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
 and Lead Plaintiff Deadline: March 27, 2017 - EconoTimes)
NEW YORK, Jan. 27, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innocoll Holdings, plc (“Innocoll” or the “Company”) (NASDAQ:INNL) and certain of its officers, on behalf of shareholders who purchased Innocoll securities between November 3, 2016 through December 29, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/innl.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) consequently, Defendants’ statements regarding Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food & Drug Administration (“FDA”) regarding its New Drug Application for XARACOLL, a postsurgical pain treatment and the Company’s lead product candidate. Innocoll said that the FDA stated that XARACOLL should have been categorized as a drug/device combination which would necessitate additional information. Following this news, Innocoll stock has dropped up to 66%, damaging investors.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/innl or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
